Incyte | Операционный Доход



Operating Profit Изменить Дата
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 793M 1.39B 2024-12
Eli Lilly USD 5.15B 3.62B 2024-12
Exelixis USD 163.21M 27.13M 2025-01
Gilead Sciences USD 2.45B 1.56B 2024-12
Incyte USD 301.51M 155.43M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
MacroGenics USD -16587000 70.78M 2024-12
Merck USD 4.3B 369M 2024-12
Moderna USD -1246000000 1.18B 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Novartis USD 3.4B 193M 2024-12
Pfizer USD -409000000 5.57B 2024-12
PTC Therapeutics USD -62489000 7.98M 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Incyte Операционный Доход - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Apr 2025.